Close X
Attorney Spotlight

How did Mike DeAgro's experience co-founding a nonprofit advocacy organization lead to a career in the legal field? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Kate Hunter-Salas

Associate

Nashville
(615) 742-7822 TEL
(615) 742-0475 FAX

Kate Hunter-Salas

Associate

Nashville
(615) 742-7822 TEL
(615) 742-0475 FAX
Nashville
(615) 742-7822 TEL
(615) 742-0475 FAX

Kate Hunter-Salas concentrates her practice on investigations and litigation related to inquiries involving alleged violations of the False Claims Act (FCA), the Foreign Corrupt Practices Act (FCPA), various securities laws and other federal statutes. She represents healthcare companies in responding to government investigations concerning issues of alleged healthcare fraud and abuse. She regularly counsels clients on compliance with the FCA and defends clients related to various state and federal agency investigations.

In addition, Kate helps clients stay up-to-date on regulatory developments related to corporate compliance matters and assists clients in conducting internal investigations and preparing and implementing anti-corruption compliance programs.

Prior to joining Bass, Berry & Sims, Kate was an associate in the Washington, D.C. office of Norton Rose Fulbright. Kate earned her law degree and an LL.M. in international and comparative law from Duke University School of Law. She earned a B.A. in international relations and economics from Tufts University.

Memberships

American Health Lawyers Association (AHLA)

News

View More

Representative Experience

View More

Publications

View More

Additional Thought Leadership

Publications:

  • "Hoskins – A Limit on the U.S. Long-arm Reach over Corruption" (co-author), Fraud Intelligence (October 2015)
  • "The Dodd-Frank Act Whistleblower Provisions and the SEC Whistleblower Program in 2014" (co-author), State Bar of Texas Corporate Counsel Section Newsletter (Winter 2015)
  • "Deferred Prosecution and Non-prosecution Agreements in the United States, England, and Wales" (co-author), The Review of Securities & Commodities Regulation (February 4, 2015)

Accolades

Phi Beta Kappa

Duke Journal of Comparative & International Law – Editor-in-Chief

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.